Lung cancer clues found in chest fluid
NCT ID NCT07012759
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is looking for new biological markers in the fluid that builds up around the lungs (pleural effusion) in people with lung adenocarcinoma. Researchers will compare these markers between cancerous and non-cancerous fluid samples from 100 patients. The goal is to see if these markers can help doctors diagnose lung cancer more accurately.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a new diagnostic test that helps doctors identify lung adenocarcinoma from pleural fluid more accurately.
- What could go wrong
- This is an early-stage biomarker study, not a treatment trial. The markers may not prove reliable enough for routine clinical use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The control group consists of non-malignant pleural effusion, while the case group includes those diagnosed with pleural effusion with lung adenocarcinoma.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients requiring thoracentesis for pleural effusion drainage as determined by a physician based on clinical need. * Signed informed consent. Exclusion Criteria: * Patients under the age of 18. * Patients with malignancies other than lung adenocarcinoma.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Biomarkers are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Fu Jen Catholic University Hospital, Fu Jen Catholic University
RECRUITINGNew Taipei City, 24352, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your smartwatch could soon warn you before you crash
- Can biomarkers flag kidney risk before heart surgery?
- Your health Data's hidden patterns: can they predict what happens next?
- Can tracking fluid around the lungs improve care?
- Could a routine blood clot test predict Cancer's next move?
- Could your heart hold the key to Alzheimer's prevention?